Brief: Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026
08/06/2026 12:06
BRIEF-Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026 June 8 (Reuters) - Upstream Bio Inc UPB.O:
UPSTREAM BIO TO SHOWCASE ADDITIONAL EFFICACY DATA FROM THE PHASE 2 VIBRANT TRIAL OF VEREKITUG IN CRSWNP IN ORAL SESSION AT EAACI 2026
Source text: ID:nGNX44KMys
Further company coverage: UPB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Upstream Bio
See all newsUpstream Bio Q2 net loss narrows slightly on lower R&D costs
Upstream Bio Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
Brief: Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026
Upstream Bio Q1 net loss widens on higher R&D costs